КЛЮЧЕВЫЕ ДОСТИЖЕНИЯ В КОМБИНИРОВАННОЙ АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ ПОСЛЕДНИХ ЛЕТ

артериальная гипертензия, комбинированная терапия, приверженность, врачебная инертность, валсартан, амлодипин, гидрохлортиазид

1. Egan B.M., Basile J.N. Controlling blood pressure in 50 % of all hypertensive patients: an achievable goal in the Healthy People 2010 Report? // J. Investig. Med. – 2003. – Vol. 51, № 6. – P. 373–385.

2. Touzé E., Coste J., Voicu M. et al. Importance of in-hospital initiation of therapies and therapeutic inertia in secondary stroke prevention: Implementation of Prevention After a Cerebrovascular event (IMPACT) Study // Stroke. – 2008. – Vol. 39, № 6. – Р. 1834-1843.

3. Hyman D.J., Pavlik V.N. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine // Arch. Intern. Med. – 2001. – Vol. 160, № 15. – P. 2281–2286.

4. Кобалава Ж.Д., Котовская Ю.В., Старостина Е.Г. и др. Проблема взаимодействия врача и пациента и контроль артериальной гипертонии в России. Основные результаты научно-практической программы АРГУС-2 // Кардиология. – 2007. – Т. 47, № 3. – С. 38-47

5. Resistant hypertension: diagnosis, evaluation, and treatment, a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research // Circulation. – 2008. – Vol. 117, № 25. – P. e510-e526.

6. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. – 2009. – Vol. 27, № 11. – P. 2121-2158.

7. Phillip T. Two multicenter randomized placebo-controlled studies evaluation efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate hypertension // Clin. Ther. – 2007. – Vol. 29, № 4. – P. 563-580.

8. Conlin P.R., Spence J.D., Williams B. et al. Angiotensin II antagonists for hypertension: are there differences in the efficacy? // Am. J. Hypertens. - 2000. – Vol. 13, № 4, Pt. 1. – P. 418-426.

9. Poldermans D., Glazer R., Karagiannis S. et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension // Clin. Ther. – 2007. – Vol. 29, № 2. – P. 279–289.

10. Paulis L., Steckelings U.M., Unger T. Key advances in antihypertensive treatment // Nat. Rev. Cardiol. – 2012. – Vol. 9, № 5. – Р. 276-285.

11. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008 // J. Am. Med. Assoc. - 2010. - Vol. 303, № 20. - P. 2043-2050.

12. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group // Lancet. 1998. – Vol. 351, № 9118. – Р. 1755-1762.

13. Calhoun D.A., Lacourcière Y., Chiang Y.T., Glazer R.D. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial // Hypertension. – 2009. Vol. 54, № 1. – Р. 32-39.

14. Карпов Ю.А., Подзолков В.И., Фомин В.В., Вигдорчик А.В. Российские наблюдательные исследования валсартана и комбинированной антигипертензивной терапии на его основе // Системные гипертензии. - 2011. - № 2. - C. 2-8

15. Volpe M., Tocci G. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic // Vasc. Health Risk Manag. – 2012. – Vol. 8. – P. 371-880.

16. de la Sierra A., Barrios V. Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials // Adv. Ther. – 2012. –Vol. 29, № 5. – Р. 401-415.